Charcot-Marie-Tooth disease type 1B (CMT1b) …

Peripheral Neuropathies

Updated 12.11.2023
Released 05.07.1999
Expires For CME 12.11.2026

Charcot-Marie-Tooth disease type 1B and other CMT neuropathies associated with MPZ mutations

Authors: Florian P Thomas MD MA PhD MS, Francisco de Assis Aquino Gondim MD MSc PhD

See Contributor Disclosures

Editor: Louis H Weimer MD

Charcot-Marie-Tooth disease type 1B and other CMT neuropathies associated with MPZ mutations

In This Article

Quick Link

Introduction

Overview

Approximately one in 30,000 individuals in the general population suffers from Charcot-Marie-Tooth disease type 1B (CMT1B). Considering that the prevalence of Charcot-Marie-Tooth disease, in general, is one in 2500, this subtype is, thus, a relatively rare form. Although several new gene loci and genes are reported each year for novel subtypes, CMT1B remains among the best-studied forms. In this article, the authors include advances in our understanding of the clinical phenotype and the relation between particular mutations and the specific clinical and histological changes they cause.

Key points

	• Charcot-Marie-Tooth disease type 1B affects about one in 30,000 individuals in the general population.
	• It has an autosomal dominant inheritance pattern.
	• It is caused by mutations in the myelin protein zero gene.
	• It is usually characterized by childhood, slowly progressive peripheral nerve manifestations with distal dominant weakness, sensory loss, and limb deformities (pes cavus).
	• Demyelinating changes by neurophysiological and histological criteria are characteristic.

Historical note and terminology

The Charcot-Marie-Tooth disease entity was recognized independently in Great Britain and France (21; 117). Several earlier descriptions had been published, including a 6-generation pedigree by Eichhorst in 1873. A more severe form of inherited neuropathy was described a few years later (27). A source of confusion was the description of a progressive childhood neuropathy associated with tremor (99), which has been defined genetically (02; 92). Different forms of inheritance were later recognized (01). Since the late 1960s, the clinical and pathological spectrum has been defined, and a classification system based on seven types of hereditary motor and sensory neuropathy has been introduced, including HMSN1 and HMSN2 (31; 44).

HMSN1 is the most common form of hereditary neuropathy, characterized by severely and uniformly slowed nerve conduction velocities and primary hypertrophic myelin pathology with prominent onion bulbs and secondary axonal changes. HMSN2, on the other hand, represents the nondemyelinating neuronal type with relatively normal nerve conduction velocities and primary axonal pathology. In the neuronal form (HMSN2), characteristically, nerves are not enlarged, weakness is often less marked, and onset is generally later, although the distinction is difficult to make in individual patients by history and exam alone. Although separating neuronal and nonneuronal forms is an important etiologic and pathogenic distinction, it is noteworthy that even in HMSN1, the clinical deficits appear to correlate better with progressive axonal degeneration than slowed nerve conduction. This is not surprising, given that demyelination disturbs axonal structure and transport. The distinction between demyelinating and nondemyelinating hereditary motor and sensory neuropathy has been called into question by a report of relatively normal nerve conduction velocities suggestive of HMSN2 in younger members of a family with a myelin protein zero mutation, whereas older relatives had severely slowed conduction consistent with HMSN1 (25). As a dividing value between both forms, some use nerve conduction velocities of 38 m/s, and others use nerve conduction velocities of 42 m/s (44; 51). Because nerve conduction velocities within and between type 1 families range from normal or near normal to severely abnormal, the diagnostic usefulness of this parameter has its limits.

The hereditary motor and sensory neuropathy and Charcot-Marie-Tooth disease classification system also covers hereditary motor neuropathies and hereditary sensory neuropathies and refers to other conditions linked to specific chromosomal regions or genes such as CMT2 and CMT4 with several subtypes.

In the 1980s, linkages to chromosomes 1, 17, and X were recognized for certain Charcot-Marie-Tooth pedigrees, and Charcot-Marie-Tooth was subcategorized to cover CMT1A, aka hereditary motor and sensory neuropathy 1A (70% to 80% of CMT1), CMT1B, aka hereditary motor and sensory neuropathy 1B (4% to 5% of CMT1), and CMTX (40; 118; 62) (15% of Charcot-Marie-Tooth disease). In 1991, two groups showed that CMT1A, the most common form of CMT1 disease, was associated with a 1.5 mB duplication within chromosome 17p11.2 (96). Some 90% of CMT1A cases result from this duplication (90). Mutations in the peripheral myelin protein 22 kD (PMP22) gene, contained within the 1.5 kB duplication on chromosome 17, have been demonstrated to cause demyelinating neuropathies in Trembler and Trembler-J mice as well as in some patients with CMT1A and CMT3 (87). Moreover, transgenic mice and rats overexpressing PMP22 develop neuropathies resembling CMT1 (106). An approximately 1.5 mB long deletion of the proximal short arm of chromosome 17 is detected in most families with hereditary neuropathy with a predisposition to pressure palsy (19), whereas about 14% to 25% of patients develop hereditary neuropathy with a predisposition to pressure palsies due to other PMP22 mutations (88). The deletion includes all markers duplicated in CMT1A. Several nondeletion mutations have been identified, such as nonsense mutations with a stop codon at G183A (Trp61stop) and G372A (Trp124stop); frameshift mutations with premature termination at 19-20delAG and 434delT or with a longer transcript at 281-282insG; splice site mutations at 78+1G>T, 179+1G>C; and missense mutations at G208A (Val30Met) in exon 3 (64). A similar condition, hereditary brachial plexus neuropathy or hereditary neuralgic amyotrophy with a predilection for the brachial plexus, is not linked to the PMP22 locus but was mapped to chromosome 17q25 (91).

The 1990s also saw the identification of other Charcot-Marie-Tooth disease genes, including myelin protein zero for CMT1B and CMT3 (46; 59; 112) and the gap junction protein connexin 32 or beta 1 on chromosome Xq13.1 for the more common CMTX1 (05), whereas the rare CMTX2 was mapped to chromosome Xq24-26 (95), and the zinc-finger domain containing transcription factor early growth response 2 gene for congenital hypomyelination neuropathy and CMT1D (122). Mutations of all of these genes have been associated with several overlapping clinical phenotypes. For instance, Dejerine-Sottas syndrome is associated with PMP22 or myelin protein zero mutations or deletions (88; 121; 26).

Several disease linkages and genes have been identified, including two signal transduction genes: the N-MYC downstream-regulated gene-1 (NDRG1) on chromosome 8q24.3 for the Lom form of autosomal recessive motor and sensory neuropathy (52); the gene for the phosphatase myotubularin-related protein-2 (MTMR2) on chromosome 11q22 for autosomal recessive CMT4B (13); a cytoskeletal gene, the neurofilament light subtype gene on chromosome 8p21 for CMT2E (79); the periaxin gene on chromosome 19q13.1-2, which is regulated by EGR2, for recessive Dejerine-Sottas syndrome (12); the gene for a serine palmitoyltransferase subunit on chromosome 9q22 for hereditary sensory neuropathy type 1 (04; 24); and the gene involved in axonal organelle transport on chromosome 1p36-35 for CMT2A (130). A demyelinating neuropathy also results in some patients with Pelizaeus-Merzbacher from absent proteolipid protein expression. Mutations in the cytoskeletal protein gigaxonin have been linked to giant axonal neuropathy (14). A locus for autosomal dominant CMT2F was found on chromosome 7q11-q21 (49).

Loci with several candidate genes have been identified in two families with autosomal dominant Charcot-Marie-Tooth disease and conduction velocities between 24 and 54 m/s. These include one on chromosome 19p12-p13.2 (53); the other is associated with both large fiber loss and regeneration clusters as well as onion bulbs and uncompacted enlarged myelin lamellae on chromosome 10q24.1-q25.1 (70; 120). A recessively inherited severe form of Charcot-Marie-Tooth disease with intermediate conduction velocities is linked to chromosome 10q23 (98). Intermediate conduction velocities also occur with myelin protein zero and neurofilament light subtype gene mutations (25).

Overall, some 100 genes are known for the different forms of Charcot-Marie-Tooth disease.

Clinical manifestations

Presentation and course

Charcot-Marie-Tooth disease type 1B. Due to its insidious onset, some patients are unaware of their disease or seek medical attention only late in life. Motor symptoms predominate over sensory symptoms. Often patients complain of loss of balance, muscle weakness, and foot deformities. Some children are referred by teachers for clumsiness or toe walking. Rather than presenting with a classical Charcot-Marie-Tooth phenotype, patients seem to manifest signs and symptoms either before walking or around age 40 (108). Insertion of a charged amino acid, altering a cysteine residue in the extracellular domain, truncation of the cytoplasmic domain, or alteration of an evolutionarily conserved amino acid causes a severe early-onset neuropathy, possibly due to disruption of the tertiary structure of myelin protein zero and of the myelin-protein-zero-mediated adhesion and myelin compaction. Late-onset neuropathy is usually caused by mutations that more subtly alter myelin structure, disrupting Schwann cell-axonal interactions.

Onset. The subjective age of onset within CMT1B families may relate both to the particular mutation and the awareness of early manifestations. Some families notice delayed walking in affected offspring. Other complaints include thin lower legs, clumsiness, and difficulty running. Onset in the first decade is typical, but some patients date disease onset into young- or mid-adulthood.

Symptoms. Patients complain of tripping over objects because of foot-drop. Ankle sprains and fractures are frequent. Because of hammer toes and high arches, patients have difficulty finding shoes and suffer from painful calluses. Complaints of cold feet often associated with hair loss or leg edema are common. Pain results from pressure or strain of various structures associated with bones, joints, and tendons. Abnormal gait and scoliosis lead to back pain. Patients suffer from leg and hand cramps. Dysesthetic pain is less common than with acquired neuropathies. Manipulating small objects such as zippers, forks, or pencils may be difficult. Not infrequently, asymptomatic individuals are detected during screening of families after a relative has been diagnosed. Chronic cough occurred with a myelin protein zero Thr124Met mutation (03). In general, one should be attentive to unusual phenotypes, which could result from the co-occurrence of two different mutations, eg, periodic paralysis due to SCN4A mutation and CMT1B (47), or CMT1A and McArdle disease (114). Mild phenotypes with recurrent symptoms due to acute nerve compression in patients with demyelinating neuropathy have been associated with a heterozygous nonsense mutation (Tyr145Stop), which leads to the formation of an extracellularly truncated protein (69). A combination of distal sensorimotor symptoms, cramps, restless legs syndrome, neuropathic pain, and carpal tunnel syndrome has been reported in a family with a missense mutation (c.700G> T p.Asp234Tyr). The index patient responded to immunoglobulin and immunosuppression, suggesting a role for an autoimmune process (103). Hypertrophic caudal nerve roots can lead to cauda equina syndrome requiring surgical decompression (119). Arm monoplegia mimicking focal chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy has been described in a child with a de novo heterozygous MPZ mutation (129). Nerve biopsy did not reveal inflammation; focally folded myelin sheaths led to the diagnosis of CMT1B.

Physical findings. Cranial neuropathies are rare, but several instances of pupillary abnormalities, including light near dissociation, have been reported (06). Distally dominant weakness and muscle atrophy affect the legs more and earlier than the arms. In young children, the exam may be entirely normal with the exception of impaired heel gait. Sensation may be normal until adulthood, but distal, mild, pansensory loss is common. Reflexes are absent or depressed. Foot deformities include high arches or flat feet, hammer toes, and tight Achilles tendons. Foot deformities become more prevalent with age but are variable even among relatives of the same age (31). Gait is compromised by distal weakness, position sense, or foot deformities. Enlarged and excessively firm nerves are found in over 25% of patients, often visible in the superficial cervical nerves and palpable in the arms. Tremor occurs in up to 25% of patients. Whether it is incidental or part of the syndrome remains controversial (99; 92). Steroid-responsive forms of Charcot-Marie-Tooth disease have been recognized (32); this finding has also been reported for CMT1B (29). A phenotype with tonic pupils and conduction block was described in a patient with a p.Ile112Thr mutation in myelin protein zero (83). A slowly progressive lower motor neuron disease phenotype with subclinical sensory axonal neuropathy has also been described in Thr124Met mutations (09).

Disability. Disability may vary greatly between family members, ranging from asymptomatic individuals with minimal findings to others with severe neuropathy. Some adults require ankle foot orthoses only in the 6th decade, whereas some children may already have foot drop, proximal leg weakness, and clawing of the fingers. Significant phenotypic differences may exist among monozygotic twins, suggesting phenotypic modulation of myelin protein zero mutations by external, nongenetic influences (71). Whether disability is greater in CMT1B or CMT1A remains controversial, possibly due in part to the smaller number of patients with CMT1B available for comparison (31; 08).

Course. Clinical progression is slow in the 2nd to 4th decades. Therefore, any change in pace requires consideration of superimposed acquired or possibly independently inherited forms of neuromuscular diseases (114; 16). Charcot Marie Tooth examination scores are sensitive to the progression of axonal forms of neuropathy associated with MPZ mutations, more so for those with moderate versus mild or severe disease, but are not for demyelinating forms of the disease (41).

Genetic studies suggest that a phenotypic classification system cannot be strictly applied because mutations in the same gene can cause different clinical syndromes. Three conditions other than CMT1B are associated with myelin protein zero mutations and are also linked to mutations of other genes.

Dejerine-Sottas syndrome or hereditary motor and sensory neuropathy type 3. Dejerine-Sottas syndrome is a heterogeneous disorder caused by heterozygous or homozygous myelin protein zero or peripheral myelin protein 22 or periaxin mutations. There may also be a linkage to the chromosome 8q23-q24 region. Dominantly and recessively inherited and sporadic cases exist. Although the more severe phenotype with earlier onset of typical Dejerine-Sottas syndrome is easily distinguished from CMT1B, overlap cases are difficult to classify. As expected, there are instances of heterozygous parents with CMT1B and children with Dejerine-Sottas syndrome due to a homozygous or compound heterozygous myelin protein zero mutation.

Congenital hypomyelination neuropathy. Congenital hypomyelination neuropathy presents with neonatal hypotonia, areflexia, distal weakness, slow nerve conduction velocities, and at times with contractures or arthrogryposis. It may be due to myelin protein zero mutations that are heterozygous or homozygous in offspring of two parents with CMT1B. Milder cases overlap with Dejerine-Sottas syndrome. Other cases are caused by mutations of the early growth response 2 gene (EGR2 or Krox-20).

Charcot-Marie-Tooth disease type 2. Myelin protein zero mutation was found in several families with a clinical diagnosis of CMT2 (72; 20; 25; 104; 81; 43; 11). It has been suggested that in some of these cases, nerve conduction velocities may be normal in young patients, consistent with a CMT2 diagnosis, but they become abnormally slow with advancing age, thus, producing a CMT1 phenotype (25; 43). Incidentally, a slight decrease in conduction velocities with age was also in CMT2F (49). Mersiyanova and colleagues found a Gln333Pro mutation in the neurofilament light subtype gene on chromosome 8p21 in typical autosomal dominant CMT2 (79).

Prognosis and complications

Life expectancy is normal. Disability is highly variable and difficult to predict in young individuals, even among siblings. In general, Charcot-Marie-Tooth disease is a slowly progressive condition. If progression accelerates, other causes, such as acquired neuropathies or other inherited neuromuscular conditions, should be sought (114). Often, males are affected more than females, possibly due to a greater likelihood of nerve trauma. However, a study of myelin protein zero regulation by androgens and progesterone derivatives suggests a possible genetic course of this gender difference (68; 77). Rare complications include radiculopathies due to enlarged nerve roots.

Clinical vignette

Two patients, father and son, from a CMT1B pedigree presented with slowly progressive weakness since childhood, affecting the arms more than the legs, and numbness in the hands and feet (115). They denied recurrent focal weakness, liability to pressure palsies, or pain. Multiple living male and female relatives from four generations were affected. They carried a codon 96 mutation that substituted a positively charged lysine for a negatively charged glutamate in the extracellular region (46; 112).

Findings were similar in father and son, but more pronounced in the former. Both had pes cavus. The father had enlarged, firm, peripheral nerves. Muscle strength was reduced to 4/5, worse distally. Deep tendon reflexes were absent. Plantar responses were flexor. All sensory modalities were impaired.

Laboratory and electrophysiological studies in the father revealed normal B12, folate, and lead levels, negative myelin-associated glycoprotein and GM1 antibody titers, and serum protein electrophoresis.

No sensory or motor responses were obtained with surface recordings. Needle examination of the left median nerve revealed motor nerve conduction velocities of 11 m/s (lower normal value is 49 m/s), and a compound motor action potential amplitude of 0.3 mV (lower normal value is 5 mV). Sensory responses and F waves were absent. Electromyography revealed minimal spontaneous activity with high amplitude motor unit potentials.

Sural nerve biopsy findings were similar in father and son. Semithin cross-sections of nerve showed a reduction of myelinated fiber density. Many remaining fibers had thin myelin sheaths. Frequent small onion bulbs and scattered tomacula were found.

The myelinated fiber density was 250/mm2 in the father and 3147/mm2 in the son. Histometric measurements showed a unimodal distribution of myelinated fibers with a shift of the peak to diameters between 1 and 4 µm in the father and a bimodal distribution with one peak between 1 and 4 µm and a second peak at 6 µm in the son. Most of the fibers larger than 5 µm in diameter had tomacula.

Teased fibers and longitudinal semithin sections revealed sausage-shaped expansions of myelin located in both the paranodal and internodal regions in virtually all fibers. Segmental remyelination was found in all teased myelinated nerve fibers.

Tomacula in Charcot-Marie-Tooth disease type 1B (light microscopical appearance)

(A) Semithin cross-section shows a marked depletion of myelinated nerve fibers. Scattered onion bulbs consist of concentrically arranged Schwann cell processes (arrow heads), some without a central myelinated fiber. Several myelin...

Ultrathin sections demonstrated that the tomacula consisted of closely apposed, redundant loops of myelin sheath wound around or layered on one side of a thinly myelinated fiber.

Tomacula in Charcot-Marie-Tooth disease type 1B (electron microscopy)

Ultrastructure of a representative tomaculum. A redundant fold of myelin is wrapped nearly twice around the axon. The membranes of this fold are compacted about the original myelin sheath (19 lamellae) to form a hypermyelinated st...

Incorporation of the altered myelin protein zero into the myelin sheath was demonstrated immunohistochemically.

Tomacula in Charcot-Marie-Tooth disease type 1B (immunohistochemical appearance)

Sural nerve, indirect immunofluorescence. Cryosections were incubated with a rabbit polyclonal antiserum to myelin protein zero, followed by a Texas red-conjugated antibody to rabbit IgG. The antigen is expressed on myelin sheaths...

Biological basis

Etiology and pathogenesis

Multiple differing mutations in the myelin protein zero gene, located in the q21.3-q22 region on chromosome 1, have been identified in families with inherited motor sensory neuropathies. Clinical phenotypes include CMT1B, Dejerine-Sottas syndrome, congenital hypomyelination, and surprisingly, also CMT2. Some 55 point mutations in different exons have been identified. These clusters are in exons 2 and 3, with some in exons 4 and 6 (86).

Protein structure. Myelin protein zero is an integral type I membrane protein of compact peripheral nerve myelin, where it constitutes more than 50% of total protein and links adjacent lamellae and stabilizes the myelin assembly. Expression in the CNS of mutated protein might be responsible for features such as dysphagia and deafness (20; 75; 101). Its gene spans about 7 kb of DNA, is composed of 6 exons, and encodes a protein of 219 amino acids (248 with exon 1, the signal peptide) with an apparent molecular weight of 28 kd. It contains a highly basic intracellular domain (exons 5 and 6, amino acid residues 151 to 219), a single membrane-spanning domain (exon 4, residues 125 to 150), and an extracellular domain (exons 2 and 3, residues 1 to 124) that resembles the immunoglobulin VH domain in length and predicted secondary structure and carries the L2/HNK-1 carbohydrate epitope, a mediator of membrane adhesion. Myelin protein zero is, thus, a member of the immunoglobulin supergene family and a cell adhesion molecule, but also has homology to the human sodium channel beta-1 subunit. Posttranslational modifications include acylation at Cys153, serine/threonine and developmentally regulated tyrosine phosphorylation, sulfation, N-glycosylation at Asp122 in exon 3, which is required for myelin adhesion, and a Cys21-Cys127 disulfide bond in the immunoglobulin domain.

Structure of myelin protein zero

Myelin protein zero relative to the myelin membrane. Characteristic mutations are indicated. (Contributed by Dr. Florian Thomas.)

As a homophilic tetrameric adhesion molecule, its extracellular domain adheres to the corresponding domains of myelin protein zero molecules on apposing membranes through hydrogen bonds and polar interactions and, thus, contributes to myelin compaction and formation of the interperiod (minor dense) line seen by electron microscopy. However, the colocalization of myelin protein zero and peripheral myelin protein 22 in compact myelin and the presence of the L2/HNK-1 carbohydrate epitope on peripheral myelin protein 22 suggest that these two molecules may also interact in a heterophilic interaction. In vitro, complex formation in the myelin membrane of myelin protein zero and peripheral myelin protein 22 was demonstrated (30). The basic cytoplasmic domain interacts through its positive charge with negatively charged head groups of membrane phospholipids, thereby linking apposed membrane surfaces and contributing to the formation of the major dense line of myelin. It undergoes phosphorylation and dephosphorylation on serine/threonine and tyrosine residues and, thus, participates in signal transduction.

Human mutations. Over 100 mutations in myelin protein zero have been detected and correlated with clinical phenotypes that include CMT1B, CMT2, Dejerine-Sottas syndrome, and congenital hypomyelination neuropathy (86). More than half are missense, the rest nonsense, frameshift, deletion, or insertion mutations. The vast majority are in exons 2 and 3 of the extracellular domain, where they can disturb myelin compaction. Others are in the transmembrane (exon 4) or cytoplasmic (exons 5 and 6) domains or its margins. Some mutations are associated with particular clinical, electrophysiological, and histological phenotypes. Two conservative polymorphisms exist at Gly200 and Ser228 in exons 5 and 6 in the intracellular domain.

Structure of myelin protein zero

Myelin protein zero relative to the myelin membrane. Characteristic mutations are indicated. (Contributed by Dr. Florian Thomas.)

Most mutations are associated with typical CMT1B phenotypes. Most are single amino-acid substitutions in exons 2 and 3 of the extracellular domain. Copy number mutations can also cause CMT1B demyelinating phenotype (48; 67). Some are single amino-acid deletions or mutations resulting in a truncated myelin protein zero (Gly74 frame shift, stop codon at codons 53, 125, and 152). A Ser34 deletion resulted in absent myelin protein zero protein, as did a Gly24 frameshift mutation, which caused CMT1B in heterozygous parents and Dejerine-Sottas syndrome in their children. A mild late-onset phenotype with nerve conduction velocities of 32 m/s resulted from an Asp122Glu substitution, which eliminates the crucial N-glycosylation site (10). Mild phenotypes were associated with Ser63del (80) and c.160_167delTCCCGGGT mutations (22). Roussy-Levy syndrome is associated with a heterozygous Asn131Lys substitution in the extracellular domain of myelin protein zero (92). Steroid-responsive CMT1B was reported with a Ile99Thr substitution in exon 3 of the extracellular domain (29). There is additional evidence that patients with CMT1B and other CMT forms may be more prone to immune-mediated neuropathies. A patient with subclinical neuropathy and a de novo heterozygous null mutation (p.Tyr68Ter) became symptomatic due to superimposed chronic inflammatory demyelinating polyneuropathy and improved with immunoglobulin therapy (16). CIDP-like characteristics were also described with a p.Ser63del mutation (36). Mild recurrent CMT1B with an exon 3 Glu71stop mutation that may reduce the amount of myelin protein zero was associated with sensitivity to intense manual work, demyelination and remyelination, axonal loss, and myelin uncompaction (61). A double mutation with a de novo extracellular Val42 deletion and an intracellular Ala221Thr substitution were both found in a 25-year-old woman with progressive neuropathy since the age of 2 years. Her father had two normal alleles, whereas her mother had the Ala221Thr substitution (93). A CMT2 phenotype was associated with three myelin protein zero mutations: (1) Ile89Asn, (2) Val92Met, and (3) Ile162Met (11). A mixed demyelinating and axonal neuropathy, pes cavus, and pupillary light-near dissociation were associated with myelin protein zero mutations His81Arg and Val113Phe on the same allele (06); the phenotype was less severe than in two instances of isolated His81Arg mutations (107). Although these two amino acids are not close together in 3-dimensional models, an interaction between them cannot be excluded. Pupillary abnormalities have also been reported with Thr124Met and Asp75Val mutations (06).

The mechanism underlying expression of a predominantly axonal versus a predominantly demyelinating mutation for a given myelin protein zero mutation is unclear, but defective myelin or myelin-axon interactions are the likely causes for both (11; 45). Skin biopsy analysis in a family with minimally slowed nerve conduction velocities and a mutation that abolishes a 5' donor site recognition in intron 4 revealed normal myelin protein zero levels but loss of the myelin protein zero transmembranous exon 4 and a frame-shifted cytoplasmic domain, which is expected to abolish homotypic adhesion (100). An autopsy study of a case of late-onset neuropathy with a His10Pro myelin protein zero mutation revealed axonal loss, axolemmal reorganization, and focal nerve enlargements with myelin protein zero and ubiquitin deposits in the inner myelin and periaxonal spaces with minimal demyelination (65).

Rare mutations are associated with central nervous system or cranial nerve manifestations. Thr124Met and Asp75Val mutations were found in families with variable combinations of a CMT2 phenotype, dysphagia, deafness, or pupillary abnormalities (20; 25; 81). Indirect support for a pathogenic role of such mutations comes from a myelin protein immunization study that resulted in deafness in experimental mice (75). An exon 3 Arg81His mutation in the extracellular domain was found in a girl with severe CMT1B or Dejerine-Sottas syndrome, thickened trigeminal nerves, and prolonged conduction times from the eighth cranial nerve to the pontomedullary portions of the auditory pathway (107). A His39Pro myelin protein zero mutation in the extracellular domain was linked to premature hearing loss and restless leg symptoms (54). Reyes-Marin and colleagues reported a homozygous mutation leading to late-onset demyelinating phenotype with brain white matter lesions (97).

Some mutations are associated with severe phenotypes. In general, myelin protein zero mutations in the transmembrane domain are associated with more severe phenotypes. However, a G1064C/Gly163Arg mutation was linked to a mild phenotype (33). Substitutions such as Cys63Ser, Ser34Cys, Arg69Cys, and Trp72Cys in exons 2 and 3 of the extracellular domain are associated with particularly severe manifestations. Dejerine-Sottas syndrome has been linked to a Ser34Cys substitution, which can lead to free thiol group and disulfide aggregates and may act as dominant negative, thus, inactivating normal myelin protein zero expressed from the other allele. Not surprisingly, Dejerine-Sottas syndrome is also seen in the homozygous children of parents with CMT1B and heterozygous Gly74 frame shift or Phe35 deletion mutations. A Gln,Pro,Tyr,Ile86-89His,Leu,Phe substitution in exon 3 that could greatly alter protein structure was detected in another patient with Dejerine-Sottas syndrome (109). A severe demyelinating phenotype was associated with a missense mutation, D32N, that resulted in a glycosylation sequence and a hyperglycosylated protein with partial retention in the Golgi apparatus and disrupted intercellular adhesion (94).

Dejerine-Sottas syndrome or congenital hypomyelination neuropathy also occurs with mutations in exon 4 of the cytoplasmic domain and exons 5 or 6 of the transmembrane domain or its margins, resulting in substitutions, frame-shifts, or stop codons: Gly167Arg, Leu145frame shift, Ala192frame shift, Gln186stop, Val203frame shift. An Ala221 insertion that causes Dejerine-Sottas syndrome disrupts a tyrosine phosphatase recruitment site at the C terminus; this is evidence of the importance of signal transduction properties of myelin protein zero (127). However, intracellular truncation mutations are not inevitably associated with a severe phenotype, as evidenced by a family with a heterozygous Gly206stop mutation leading to removal of four fifths of the protein constituting the intracellular domain. Despite this truncation, no affected relatives had Dejerine-Sottas syndrome or other severe phenotypes; intrafamilial variability was marked with one family member displaying only pes cavus and conduction slowing and another displaying only hammertoes (105). The authors suggested that the ability of the mutated protein to form intracellular tetramers with other myelin protein zero would determine the severity of the phenotype. This interaction might be impossible with large truncations, thus, allowing the unmutated protein expressed from the other allele to establish normal protein complexes, whereas smaller truncations would connect to other proteins and have a dominant negative effect. Alternatively, mRNA from the mutated allele could be unstable and decay.

Mutations associated with Charcot-Marie-Tooth disease type 1-Charcot-Marie-Tooth disease type 2 overlap syndromes. Reports indicate that myelin protein zero mutations are associated not only with predominantly demyelinating CMT1-like neuropathies but also with axonal CMT2-like neuropathies. A Thr124Met mutation in the extracellular domain and close to the Asp122 glycosylation site and the Cys127 involved in a disulfide bridge was detected in several reports. De Jonghe and colleagues reported families with a dominantly inherited neuropathy initially classified as CMT2 with late-onset weakness, marked sensory abnormalities, occasional deafness, and pupillary abnormalities (25). Most patients have at least one nerve conduction velocity greater than 38 m/s. Although demyelinating features were found in biopsies, axonal degeneration was also prominent, as were tomacula. Several CMT2-like families carry this or mutations such as Asp75Val, Ala76Val, Val113IIe, Tyr119Cys, or Asp61Gly (125; 72; 104; 81; 85).

A Ser44Phe mutation in the extracellular domain was detected in a CMT2 family with nerve conduction velocities greater than 42 m/s (72). A family with nerve conduction velocities greater than 38 m/s and frameshift mutation due to 1 bp deletion at codon 102 leading to myelin protein zero truncation was reported. Heterozygous offspring had a CMT2-like phenotype, whereas homozygous offspring had Dejerine-Sottas syndrome (113; 121; 89). Axonal features in these cases might result from mutations that affect axon-myelin interactions more than myelin compaction (123; 113). An intracytoplasmic domain Lys236del mutation associated with variable penetrance was reported ranging from asymptomatic to foot deformities and nonuniform intermediate range conduction velocities (111). Velocities were normal in a 15-year-old clinically affected girl, suggesting age-dependent progressive slowing.

Dominant negative effects. In part, the effect of a heterozygous myelin protein zero mutation is explained by a 50% reduction in functional gene dosage. However, the clinical, electrophysiologic, and histological differences between patients harboring different mutations may additionally be due to various consequences of particular mutations on the interaction of abnormal with normal myelin protein zero units in the tetramer and with other cellular proteins. Abnormal protein would, therefore, exert a dominant negative effect, thus, reducing the amount of functional myelin protein zero to under 50% and causing a more severe phenotype. Without this dominant negative effect, a milder form of CMT1B would result.

Experimental systems. Both in vitro and in vivo models confirm and expand the phenotype-genotype correlations from human studies. Cell culture studies show that mutated myelin protein zero differs from wild-type protein in adhesiveness and complex formation. Coexpression of wild-type and mutated myelin protein zero confirms that the biological consequences of specific mutations vary: some mutations inactivate wild-type protein, whereas others do not. This fact may explain the variation between families. In Schwann cell cultures, glucocorticoids stimulate (directly or indirectly) the activity of both the myelin protein zero and PMP22 gene promoters; this may explain the benefit of steroids in some cases of CMT1 in particular and in immune-mediated neurologic conditions in general (28). Schwann cells from myelin protein zero knockout mice downregulate PMP22 and upregulate myelin associate glycoprotein and proteolipid protein; mistargeting of these and other proteins to inappropriate cellular compartments and dysregulation of other adhesion molecules also occur, indicating that myelin protein zero is involved in the regulation of myelin gene expression (127). Overexpressed myelin protein zero also leads to its mistargeting and myelination arrest (128). An in vitro study of an exon 2 Ile62Phe mutation, which in humans causes irregular myelin folding (84), revealed abnormal cell aggregation relative to other mutations and wild-type myelin protein zero, suggesting that this protein domain is crucial for normal myelin adhesion and compaction (76).

Mice homozygous for a myelin protein zero deletion develop severe hypomyelination with prolonged distal motor latencies, clinical and electrical neuromyotonia, and reduced nerve conduction velocities (73; 78; 131). Reduced axon diameter, distal axon loss, and myelin uncompaction are found. Many other myelin proteins are reduced or show altered intracellular distribution. This phenotype resembles that of congenital hypomyelination neuropathy or Dejerine-Sottas syndrome. Mice heterozygous for a myelin protein zero deletion are normal at birth but, similar to CMT1B, later develop impaired nerve conduction, neuromyotonia, demyelination, and onion bulbs. They also display a severe age-dependent disturbance in the expression and localization of other myelin proteins. Mice engineered to carry myelin protein zero mutations resulting in congenital hypomyelination neuropathy (S63C and S63del) developed a syndrome mimicking the human disease. Genetic analysis indicated that pathologic changes arose from a gain-of-function effect (126).

In addition, Cx32 and myelin protein zero deficient mice exhibit similar immunopathogenic mechanisms with immune-mediated demyelination (17; 56). In myelin protein zero deficient mice, T-lymphocytes and macrophages are increased in demyelinating nerves (17), suggesting that immune-mediated demyelination may play an important role in hereditary neuropathies. A role for autoimmunity in CMT1B is also suggested by cases that respond to steroids, immunoglobulin, and immunosuppression (124; 103).

Diagnostic workup

The purpose of studies in patients with a possible inherited neuropathy is to confirm or refute this working diagnosis and to ascertain the presence of a treatable neuropathy, which might be the sole or a superimposed condition. This workup should include tests that address causes of neuropathies such as endocrine, infectious, and immunological abnormalities, vitamin and nutritional deficiencies, and nerve compression.

Spinal fluid analysis. Although lumbar puncture is rarely indicated, protein levels are usually normal in patients with CMT1B but may be elevated above 100 mg/dL. By contrast, it is elevated in most cases of Dejerine-Sottas syndrome. In a comparison of CMT1A, CMT1B, and CMTX CSF protein (and CK), elevations were more common with myelin protein zero mutations (45).

Genetic testing. Patients whose clinical phenotype, family history, or electrodiagnostic studies suggest that they might have an inherited neuropathy should be genotyped. This is important because clinical examination and electrodiagnostic studies often cannot definitively establish a precise diagnosis due to the overlap between clinical syndromes and the significant variability between family members with an identical genotype. Genotyping permits sound genetic and prognostic counseling and advances the scientific understanding of phenotypes. The importance of genetic testing was illustrated by the report of two sisters with severe CMT1 and healthy parents, for whom autosomal recessive inheritance had been presumed until genetic testing identified low-level somatic and germline mosaicism of a myelin protein zero extracellular domain Gly74Glu mutation in the healthy mother, which she transmitted to her affected daughters (38).

Electrodiagnostic studies. Compared with acquired neuropathies, CMT1 is typically characterized by diffuse and uniform conduction slowing. Because nerve conduction is stable and secure in contradistinction to acute or chronic inflammatory demyelinating polyradiculoneuropathies, conduction block and dispersion are rare. Conduction values are symmetric, and there are few differences between proximal and distal nerve segments. Nerves often are refractory to stimulation or require higher amplitude and prolonged stimulation.

Nerve conduction velocities have limited diagnostic value among patients with inherited neuropathies because of the extreme range. In a study of a single CMT1B pedigree, nerve conduction velocities were significantly slower than in patients with CMT1A (07), whereas in a comparison of 119 patients with CMT1A and 10 with CMT1B, no differences were found (08). Because of the rarity of CMT1B relative to CMT1A, such studies are difficult to assess and may reflect particular characteristics of single myelin protein zero mutations. Among patients with CMT1A, median nerve conduction velocities varied by 30 m/s (with a range from 10 to 42 m/s) within families by 20 m/s and by 10 m/s among siblings (35). The variability among patients with CMT1B may be more limited, but patients with myelin protein zero mutations, a CMT2-like phenotype, and nerve conduction velocities in the normal or intermediate range have been reported (125; 72; 102; 20; 74). A study of 205 Charcot-Marie-Tooth disease patients with PMP22, myelin protein zero, and Cx32 mutations demonstrated that depending on the specific myelin protein zero mutation, CMT1B can present with phenotypes that do not overlap within families: (1) pure axonal features with preserved conduction velocities, and (2) exclusively demyelinating changes; sensorineural deafness, Adie pupil, and CK elevations were more prevalent in the axonal group (45).

After the peripheral nerves reach their mature state in early childhood, nerve conduction velocities in patients with Charcot-Marie-Tooth disease change little during life, even as disease manifestations progress. Thus, they do not correlate with severity. However, patients with extremely slow nerve conduction speeds likely have a more severe phenotype. There is some debate about the relationship between specific mutations and patterns of conduction slowing (63). Late-onset axonal neuropathy due to myelin protein zero mutation has been reported in a patient who was initially thought to have amyloid neuropathy (15). Despite the presence of mild macroglossia and positive changes on abdominal fat biopsy, the lack of autonomic changes and other systemic features led to the correct genetic diagnosis.

Imaging studies. Patients with CMT1B have larger median and vagus nerves than controls (18). Cranial nerve size did not differ between patients with and without cranial neuropathies. Lower limb MRI assesses the fat fraction in different muscles and is a marker of disease progression (82). Whole-body neurography can demonstrate plexus and nerve thickening (23).

Neuropathologic studies. Most nerve biopsies from patients with CMT1B show evidence of a hypertrophic demyelinating neuropathy with onion bulbs as evidence of chronic remyelination and loss of myelinated fibers, preferentially those of large diameter (31; 44). Two autopsies have been reported. One study revealed hypertrophy and endoneurial fibrosis in peripheral and spinal nerves (07). The other, of a patient with His10Pro mutation, showed prominent axonal pathology, including focal axonal enlargements and thin myelin but not segmental demyelination; there was also disorganization of paranodal expression of molecules involved in axon-glia interaction and of potassium channels (66).

As stated above, a link between specific myelin protein zero mutations and axonal versus demyelinating pathology was established in 11 sural nerve biopsies (45), further confirming the particular properties and potential for disruption of normal nerve metabolism of myelin protein zero domains. Thomas and colleagues first described prominent tomacula in two patients with CMT1B from a family with a Lys96Glu mutation (115). The association of tomacula or focally folded myelin with myelin protein zero mutations has since been confirmed for extracellular domain (exons 2 or 3) substitutions such as Ser49Leu, Lys96Glu, Lys101Arg, Lys130Arg, lle135Leu, Ile106Leu, and Asp109Asn, whereas uncompacted myelin shape was found in 23% to 68% of fibers with mutations that include Thr4Ile, Arg69Cys, Arg69His, Asn131Lys, and Ser34 deletion (42; 60; 84; 39; 76; 57). Patients with mutations in the intracellular domain (exons 5 and 6) and in the exon 4 transmembrane domain (Gln186stop) or its margins showed severe hypomyelination and myelin uncompaction. A link was demonstrated between particular extracellular domain mutations and ultrastructural phenotypes. One study reported widening or irregularity of the extracellular apposition alone with a Ser34 deletion and a Arg69Cys mutation, widening at the extracellular and cytoplasmic appositions with a Arg69His mutation, the presence of focal bridges in the widened extracellular space with a Arg69His mutation, and diminished (Arg69Cys) or absent (Arg69His) staining of the double intraperiod line (55). Surprisingly, not only typical demyelination and remyelination, but also intracellular myelin uncompaction at the major dense line, was associated with an exon 3 Arg98Cys mutation in the extracellular domain in a patient with delayed motor development, typical Charcot-Marie-Tooth disease as an adult, and nerve conduction velocities less than 10 m/s (58); the same mutation was detected in a severely affected infant who died at 22 months (42). Mutational introduction of cysteine residues is likely to compromise the correct disulfide bond and, thus, protein structure.

It should be noted that tomaculous neuropathy is also a hallmark of hereditary neuropathy, with liability to pressure palsy resulting from a 1.5 MB deletion at chromosome 17p11.2 and rare peripheral myelin protein 22 nonsense mutations. Furthermore, Bolino and colleagues linked autosomal recessive CMT4B with focally folded myelin sheaths to several mutations in a signal transduction gene, MTMR2, resulting in a lack of functional protein and possibly in constitutive phosphorylation of an unknown substrate and myelin overgrowth (13). Tomaculum formation and myelin uncompaction were also reported in CMT1A with a peripheral myelin protein 22 Asp37Val substitution in the first extracellular loop of the PMP22 protein, which may contribute to a heterophilic interaction with P0 (37); we had suggested that myelin protein zero and peripheral myelin protein 22 act in parallel or have different roles along one functional pathway (115). This is supported by the demonstration that myelin protein zero and peripheral myelin protein 22 form complexes in the myelin membrane in vitro (30).

Dejerine-Sottas syndrome and congenital hypomyelination neuropathy are characterized by more severe hypo- and demyelination and axonal loss.

Management

It is particularly important to prevent, look for, and treat acquired neuropathies as well as to avoid compression neuropathies. This may require adjustments in lifestyle and avoidance of job-related nerve injury.

Neurotoxic drugs. Patients, family members, and physicians must be aware of drugs that can affect the peripheral nervous system. Drugs with various degrees of nerve toxicity include the following:

Definite high risk
	• Vincristine
Moderate to significant risk
	• Amiodarone • Bortezomib • Cisplatin, Oxaliplatin • Colchicine • Dapsone • Dichloroacetate • Didanosine (ddI) • Disulfiram • Gold salts • Metronidazole (extended use) • Misonidazole (extended use) • Nitrofurantoin • Nitrous oxide • Perhexiline (not used in the United States) • Pyridoxine (Vitamin B6) (high doses) • Stavudine (d4T) • Suramin • Taxols (Paclitaxel) • Thalidomide • Zalcitabine (ddC)
Uncertain or minor risk
	• 5-Fluorouracil • Adriamycin • Almitrine (not in the United States) • Chloroquine • Cytarabine • Ethambutol • Etoposide (VP-16) • Fluoroquinolone • Gemcitabine • Griseofulvine • Hexamethylmelamine • Hydralazine • Ifosfamide • Isoniazid • Mefloquine • Penicillamine • Phenytoin • Podophyllin • Sertraline • Statins • Tacrolimus • Zimeldine (not in the United States) • Interferon
Negligible or doubtful risk
	• Allopurinol • Amitriptyline • Chloramphenicol • Chlorprothixene • Cimetidine • Clioquinol • Clofibratel • Cyclosporin A • Enalapril • Glutethimide • Lithium • Phenelzine • Propafenone • Sulfonamides • Sulfasalazine

Nutritional and vitamin deficiencies. Patients should maintain a well-balanced diet and avoid obesity, which can contribute to spinal root disease and certain entrapment neuropathies (meralgia paresthetica).

Physical therapy and prosthetics. Physical therapy is often required to prevent and treat joint deformities.

Prosthetic devices such as ankle-foot orthoses can prevent Achilles tendon shortening and extend near-normal ambulation. At times, boots can delay the need for such ankle braces. Thick-handle tools and cutlery can render certain activities of daily living easier.

Pain. Pain may result from joint deformities or compensatory overuse of certain muscle groups. Some types of pain may respond to nonsteroidal antiinflammatory drugs. Dysesthetic pain may occur but is not typical; it responds to antidepressants such as amitriptyline, desipramine, or paroxetine and to anticonvulsants such as gabapentin or carbamazepine.

Surgery. Depending on the degree of foot deformities, patients may benefit from Achilles tendon lengthening, tendon transfers, hammertoe correction, and release of the plantar fascia.

Experimental therapy. The introduction of recombinant DNA encoding normal myelin protein zero into the nerves of myelin protein zero knock-out mice is being investigated as a therapeutic strategy. Another approach explores neurotrophin gene transfer into the spinal cord to prevent secondary axonal changes in models of Charcot-Marie-Tooth disease. ACE-083, a locally acting muscle therapeutic in the TGF β family that upregulates contractile muscle protein synthesis, increased muscle mass in a phase 2 trial of patients with CMT1 and CMTX (116).

Media

References

01: Allan W. Relation of hereditary pattern to clinical severity as illustrated by peroneal atrophy. Arch Intern Med 1939;63:1123-31.
02: Auer-Grumbach M, Strasser-Fuchs S, Wagner K, Korner E, Fazekas F. Roussy-Levy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2. J Neurol Sci 1998;154:72-5. PMID 9543325
03: Baloh RH, Jen JC, Kim G, Baloh RW. Chronic cough due to Thr124Met mutation in the peripheral myelin protein zero (MPZ gene). Neurology 2004;62(10):1905-6. PMID 15159512
04: Bejaoui K, Wu CY, Sheffler MD, et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 2001;27:261-2. PMID 11242106
05: Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993;262:2039-42. PMID 8266101
06: Bienfait HM, Baas F, Gabreels-Festen AA, et al. Two amino-acid substitutions in the myelin protein zero gene of a case of Charcot-Marie-Tooth disease associated with light-near dissociation. Neuromuscul Disord 2002;12:281-5. PMID 11801400
07: Bird TD, Kraft GH, Lipe HP, Kenney KL, Sumi SM. Clinical and pathological phenotype of original family with Charcot-Marie-Tooth type 1B: a 20-year study. Ann Neurol 1997;41:463-9. PMID 9124803
08: Birouk N, Gouider R, Le Guern E, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 1997;120:813-23. PMID 9183252
09: Bisogni G, Romano A, Conte A, et al. Thr214Met myelin protein zero mutation mimicking motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degen 2022;23:299-304. PMID 34210210
10: Blanquet-Grossard F, Pham-Dinh D, Dautigny A, et al. Charcot-Marie-Tooth type 1B neuropathy: a mutation at the single glycosylation site in the major peripheral myelin glycoprotein Po. Hum Mutat 1996;8:185-6. PMID 8844219
11: Boerkoel CF, Takashima H, Garcia CA, et al. Charcot-Marie-Tooth disease and related neuro-pathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002;51:190-201. PMID 11835375
12: Boerkoel C, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001;68:325-33. PMID 11133365
13: Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nature Genet 2000;25:17-9. PMID 10802647
14: Bomont P, Cavalier L, Blondeau F, et al. The gene mutated in giant axonal neuropathy encodes for gigaxonin, a novel member of the cytoskeletal BTB/Kelch repeat family. Nat Genet 2000;26:370-4. PMID 11062483
15: Briani C, Adami F, Cavallaro T, Taioli F, Ferrari S, Fabrizi G. Axonal neuropathy due to myelin protein zero mutation misdiagnosed as amyloid neuropathy. Muscle Nerve 2008;38(1):921-3. PMID 18563718
16: Cardellini D, Zanette G, Taioli F, et al. CIDP, CMT1B, or CMT1B plus CIDP? Neurol Sci 2021;42:1127-30. PMID 33070202
17: Carenini S, Maurer M, Werner A, et al. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol 2001;152:301-8. PMID 11266447
18: Cartwright MS, Brown ME, Eulitt P, Walker FO, Lawson VH, Caress JB. Diagnostic nerve ultrasound in Charcot-Marie-Tooth disease type 1B. Muscle Nerve 2009;40(1):98-102. PMID 19533637
19: Chance PF, Alderson MK, Leppig KA, et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993;72:143-51. PMID 8422677
20: Chapon F, Latour P, Diraison P, Schaeffer S, Vandenberghe A. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry 1999;66:779-82. PMID 10329755
21: Charcot JM, Marie P. Sur une forme particulière d'atrophie musculaire, souvent familiale, débutant par les pieds et les jambes et atteignant plus tard les mains. Rev Méd Paris 1886;6:97-138.
22: Chavada G, Rao DG, Martindale J, Hadjivassiliou M. A novel MPZ gene mutation in exon 2 causing late-onset demyelinating Charcot-Marie-Tooth disease. J Clin Neuromuscul Dis 2012;13:206-8. PMID 22622165
23: Chhabra A, Carrino JA, Farahani SJ, et al. Whole-body MR neurography: prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging 2016;44(6):1513-21. PMID 27126998
24: Dawkins JL, Hulme DJ, Brahmbhatt SB, Auer-Grumbach M, Nicholson GA. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 2001;27:309-12. PMID 11242114
25: De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999;122:281-90. PMID 10071056
26: De Jonghe P, Timmerman V, Nelis E, et al. Charcot- Marie-Tooth Disease and related peripheral neuropathies. J. Periph Nerv Sys 1997;4:370-87. PMID 10975746
27: Dejerine J, Sottas J. Sur la névrite interstitielle hypertrophique et progressive de l'enfance. Comp Rend Soc Biol 1893;45:63-96.
28: Desarnaud F, Bidichandani S, Patel PI, Baulieu EE, Schumacher M. Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. Brain Res 2000;19:865:12-6. PMID 10814728
29: Donaghy M, Sisodiya SM, Kennett R, McDonald B, Haites N, Bell C. Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. J Neurol Neurosurg Psychiatry 2000;69:799-805. PMID 11080236
30: D’Urso D, Ehrhardt P, Muller HW. Peripheral myelin protein 22 and protein zero: a novel association in peripheral nervous system myelin. J Neurosci 1999;19:3396-403. PMID 10212299
31: Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968;18:603-18. PMID 4297451
32: Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc 1982;57:239-46. PMID 7070119
33: Eggers SD, Keswani SC, Melli G, Cornblath DR. Clinical and genetic description of a family with Charcot-Marie-Tooth disease type 1B from a transmembrane MPZ mutation. Muscle Nerve 2004;29(6):867-9. PMID 15170620
34: Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord 1991;1:19-29. PMID 1822774
35: England JD, Garcia CA. Electrophysiological studies in the different genotypes of Charcot-Marie-Tooth disease. Curr Opin Neurol 1996;9:338-42. PMID 8894408
36: Escorcio-Bezerra ML, Pinto WB, Bichuetti DB, et al. Immune-mediated inflammatory polyneuropathy overlapping Charcot-Marie-Tooth 1B. J Clin Neurosci 2020;75:228-31. PMID 32201027
37: Fabrizi GM, Cavallaro T, Taioli F, et al. Myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22. Neurology 1999;53:846-51. PMID 10489052
38: Fabrizi GM, Ferrarini M, Cavallaro T, Jarre L, Polo A, Rizzuto N. A somatic and germline mosaic mutation in MPZ/P(0) mimics recessive inheritance of CMT1B. Neurology 2001;57(1):101-5. PMID 11445635
39: Fabrizi GM, Taioli F, Cavallaro T, et al. Focally folded myelin in Charcot-Marie-Tooth neuropathy type 1B with Ser49Leu in the myelin protein zero. Acta Neuropathol 2000;100:299-304. PMID 10965800
40: Fischbeck KH, ar-Rushdi N, Pericak-Vance M, Rozear M, Roses AD, Fryns JP. X-linked neuropathy: gene localization with DNA probes. Ann Neurol 1986;20:527-32. PMID 3024556
41: Fridman V, Sillau S, Bockhorst J, et al. Disease progression in Charcot-Marie-Tooth disease related to MPZ mutations: a longitudinal study. [Epub ahead of print.] Ann Neurol 2022. PMID 36203352
42: Gabreels-Festen AA, Hoogendijk JE, Meijerink PH, et al. Two divergent types of nerve pathology in patients with different P0 mutations in Charcot-Marie-Tooth disease. Neurology 1996;47(3):761-5. PMID 8797476
43: Haneman CO, Gabreels-Festen AA, De Jonghe P. Axon damage in CMT due to mutation in myelin P0. Neuromuscul Disord 2001;11:753-6. PMID 11595518
44: Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathies types I and II. Brain 1980;118:809-18. PMID 7397478
45: Hattori N, Yamamoto M, Yoshihara T, et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain 2003;126(Pt 1):134-51. PMID 12477701
46: Hayasaka K, Himoro M, Sato W, et al. CMT neuropathy 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993;5:31-4. PMID 7693129
47: Hisama FM. Familial periodic paralysis and Charcot-Marie-Tooth disease in a 7-generation family. Arch Neurol 2005;62(1):135-8. PMID 15642860
48: Hoyer H, Braathen GJ, Eek AK, Skjelbred CF, Russell MB. Charcot-Marie-Tooth caused by a copy number variation in myelin protein zero. Eur J Med Genet 2011;54:e580-3. PMID 21787890
49: Ismailov SM, Fedotov VP, Dadali EL, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J Hum Genet 2001;9:646-50. PMID 11528513
50: Kakar R, Ma W, Dutra A, Seltzer WK, Grewal RP. Clinical and genetic analysis of CMT1B in a Nigerian family. Muscle Nerve 2003;27:628-30. PMID 12707985
51: Kaku DA, Parry GJ, Malamut R, Lupski JR, Garcia CA. Nerve conduction studies in Charcot-Marie-Tooth polyneuropathy associate with a segmental duplication of chromosome 17. Neurology 1993;43:1806-8. PMID 8414036
52: Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 2000;67:47-58. PMID 10831399
53: Kennerson ML, Zhu D, Garnder RJ, et al. Dominant intermediate Charcot-Marie-Tooth neuropathy maps to chromosome 19p12-p13.2. Am J Hum Genet 2001;69:883-8. PMID 11533912
54: Kilfoyle DH, Dyck PJ, Wu Y, et al. Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77(8):963-6. PMID 16844954
55: Kirschner DA, Szumowski K, Gabreels-Festen AA, Hoogendijk JE, Bolhuis PA. Inherited demyelinating peripheral neuropathies: relating myelin packing abnormalities to P0 molecular defects. J Neurosci Res 1996;46:502-8. PMID 8950710
56: Kobsar I, Berghoff M, Samsam M, et al. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 2003;126:804-13. PMID 12615640
57: Kochanski A, Drac H, Jedrzejowska H, Hausmanowa-Petrusewicz I. Focally folded myelin in Charcot-Marie-Tooth type 1B disease is associated with Asn131Lys mutation in myelin protein zero gene: short report. Eur J Neurol 2003;10:547-9. PMID 12940837
58: Komiyama A, Ohnishi A, Izawa K, Yamamori S, Ohashi H, Hasegawa O. De novo mutation (Arg98-->Cys) of the myelin P0 gene and uncompaction of the major dense line of the myelin sheath in a severe variant of Charcot-Marie-Tooth disease type 1B. J Neurol Sci 1997;149:103-9. PMID 9168174
59: Kulkens T, Bolhuis PA, Wolterman RA, et al. Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet 1993;5:35-9. PMID 7693130
60: Lagueny A, Latour P, Vital A, et al. Peripheral myelin modification in CMT1B correlates with MPZ gene mutations. Neuromuscul Disord 1999;9:361-7. PMID 10545037
61: Lagueny A, Latour P, Vital A, et al. Mild recurrent neuropathy in CMT1B with a novel nonsense mutation in the extracellular domain of the MPZ gene. J Neurol Neurosurg Psychiatry 2001;70:232-5. PMID 11160475
62: Lebo RV, Chance PF, Dyck PJ, et al. Chromosome 1 Charcot-Marie-Tooth disease (CMT1B) locus in the Fc-gamma receptor gene region. Hum Genet 1991;88:1-12. PMID 1683643
63: Lee Y, Soong B, Liu Y, Lin K, Kao, K, Wu Z. Median nerve conduction velocity is concordant with myelin protein zero gene mutation. J Neurol 2005;252(2):151-5. PMID 15729519
64: Lenssen P, Gabreels-Festen A, Valentijn L, et al. Hereditary neuropathies with liability to pressure palsies. Phenotypic differences between patients with the common deletion and a PMP22 frame shift mutation. Brain 1998;121:1451-8. PMID 9712007
65: Li J, Bai Y, Ianakova E, et al. Major myelin protein gene (P0) mutation causes a novel form of axonal degeneration. J Comp Neurol 2006;498(2):252-65. PMID 16856127
66: Li J, Grandis M, Krajewski KM, et al. Clinical, pathological and molecular phenotype of a human MPZ mutation: an autopsy study. Proceedings of the first European and North American Charcot-Marie-Tooth Consortium Meeting; July 8-10, 2004; Anwerpen, Belgium
67: Maeda MH, Mitsui J, Soong BW, et al. Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol 2012;71:84-92. PMID 22275255
68: Magnaghi V, Cavarretta I, Zucchi I, et al. Po gene expression is modulated by androgens in the sciatic nerve of adult male rats. Mol Brain Res 1999;70:36-44. PMID 10381541
69: Magot A, Latour P, Mussini JM, Mourtada R, Guiheneuc P, Pereon Y. A new MPZ mutation associated with a mild CMT1 phenotype presenting with recurrent nerve compression. Muscle Nerve 2008;38(2):1055-9. PMID 18663734
70: Malandrini A, Ceuterick C, Villanova M, et al. Ultrastructural findings in the peripheral nerve in a family with the intermediate form of Charcot-Marie-Tooth disease. J Submicrosc Cytol Pathol 2001;33:59-63. PMID 11686409
71: Marques W Jr, Hanna MG, Marques SR, Sweeney MG, Thomas PK, Wood NW. Phenotypic variation of a new P0 mutation in genetically identical twins. J Neurol 1999;246:596-9. PMID 10463363
72: Marrosu MG, Vaccargiu S, Marrosu G, Vannelli A, Cianchetti C, Muntoni F. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology 1998;50:1397-401. PMID 9595994
73: Martini R. P0-deficient knockout mice as tools to understand pathomechanisms in Charcot-Marie-Tooth 1B and P0-related Déjerine Sottas syndrome. Ann N Y Acad Sci 1999;883:273-80. PMID 10586252
74: Mastaglia FL, Nowak KJ, Stell R, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 1999;67:174-9. PMID 10406984
75: Matsuoka H, Cheng KC, Krug MS, Yazawa Y, Yoo TJ. Murine model of autoimmune hearing loss induced by myelin protein P0. Ann Otol Rhinol Laryngol 1999;108:255-64. PMID 10086618
76: Matsuyama W, Nakagawa M, Takashima H, Osame M. Altered trafficking and adhesion of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B. Acta Neuropathol 2002;103:501-8. PMID 11935267
77: Melcangi RC, Magnaghi V, Cavarretta I, et al. Progesterone derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible mechanisms of action. J Neurosci Res 1999;56:349-57. PMID 10340743
78: Menichella CM, Xu W, Jiang H, et al. The absence of P0 protein produces a novel molecular phenotype in Schwann cells. Ann N Y Acad Sci 1999;883:281-93. PMID 10586253
79: Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000;67:37-46. PMID 10841809
80: Miller LJ, Patzko A, Lewis RA, Shy ME. Phenotypic presentation of the Ser63Del MPZ mutation. J Peripher Nerv Syst 2012;17:197-200. PMID 22734905
81: Misu K, Yoshihara T, Shikama Y, et al. An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val). J Neurol Neurosurg Psychiatry 2000;69:806-11. PMID 11080237
82: Morrow JM, Sinclair CD, Fischmann A, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016;15(1):65-77. PMID 26549782
83: Murphy SM, Laurá M, Blake J, Polke J, Bremner F, Reilly MM. Conduction block and tonic pupils in Charcot-Marie-Tooth disease caused by a myelin protein zero p.Ile112Thr mutation. Neuromuscul Disord 2011;21:223-6. PMID 21256749
84: Nakagawa M, Suehara M, Saito A, et al. A novel MPZ gene mutation in dominantly inherited neuropathy with focally folded myelin sheaths. Neurology 1999;52:1271-5. PMID 10214757
85: Namakura C, Lin C, Ikegami T, Guldberg P, Hayasaka K. Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22, MPZ, and Cx32/GJB1 mutations. Hum Mutat 2002;20(5):392-8. PMID 12402337
86: Nelis E, Haites N, Van Broeckhoven C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Hum Mutat 1999;13:11-28. PMID 9888385
87: Nelis E, Timmerman V, De Jonghe P, et al. Rapid screening of myelin genes in CMT1 patients by SSCP analysis: identification of new mutations and polymorphisms in the protein zero gene. Hum Genet 1994;94:653-7. PMID 7527371
88: Nelis E, Van Broeckhoven C, De Jonghe P. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 1996;4(1):25-33. PMID 8800924
89: Pareyson D, Sghirlanzoni A, Bolti S, et al. Charcot-Marie-Tooth disease type 2 and P0 gene mutations. Neurology 1999;52:1110-1. PMID 10102454
90: Patel PI, Lupski JR. Charcot-Marie-Tooth disease: a new paradigm for the mechanism of inherited disease. Trends Genet 1994;10:128-33. PMID 7518101
91: Pellegrino JE, Rebbeck TR, Brown MJ, Bird TD, Chance PF. Mapping of hereditary neuralgic amyotrophy (familial brachial plexus neuropathy) to distal chromosome 17q. Neurology 1996;46:1128-32. PMID 8780104
92: Plante-Bordeneuve V, Guiochon-Mantel A, Lacroix C, Lapresle J, Said G. The Roussy-Levy family: from the original description to the gene. Ann Neurol 1999;46:770-3. PMID 10553995
93: Plante-Bordeneuve V, Parman Y, Guiochon-Mantel A, et al. The range of chronic demyelinating neuropathy of infancy: a clinico-pathological and genetic study of 15 unrelated cases. J Neurol 2001;248:795-803. PMID 11596785
94: Prada V, Passalacqua M, Bono M, et al. Gain of glycosylation: a new pathomechanism of myelin protein zero mutations. Ann Neurol 2012;71:427-31. PMID 22451207
95: Priest JM, Fischbeck KH, Nouri N, Keats BJ. A locus for axonal motor-sensory neuropathy with deafness and mental retardation maps to Xq24-q26. Genomics 1995;29:409-2. PMID 8666389
96: Raeymaekers P, De Jonghe P, Backhovens H, et al. Absence of genetic linkage of Charcot-Marie-Tooth disease (HMSN Ia) with chromosome 1 gene markers. Neurology 1991;39:844-6. PMID 2725880
97: Reyes-Marin K, Jimenez-Pancho J, Pozo L, et al. A novel myelin protein zero (V136G) homozygous mutation causing late onset demyelinating polyneuropathy with brain white matter lesions. Clin Neurol Neurosurg 2011;113:243-4. PMID 21277678
98: Rogers T, Chandler D, Angelicheva D, et al. A novel locus for autosomal recessive peripheral neuropathy in the EGR2 region on 10q23. Am J Hum Genet 2000;67:664-71. PMID 10915613
99: Roussy G, Levy G. Sept cas d'une maladie familiale particulière. Rev Neurol 1926;45:427-50.
100: Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B. Neurology 2006;67(7):1141-6. PMID 17030746
101: Sato Y, Kimura M, Yasuda C, et al. Evidence for the presence of major peripheral myelin glycoprotein P0 in mammalian spinal cord and a change of its glycosylation state during aging. Glycobiology 1999;9:655-60. PMID 10362834
102: Schiavon F, Rampazzo A, Merlini L, Angelini C, Mostacciuolo ML. Mutations of the same sequence of the myelin P0 gene causing two different phenotypes. Hum Mutat 1998:S217-9. PMID 9452091
103: Schneider-Gold C, Kötting J, Epplen JT, Gold R, Gerding WM. Unusual Charcot-Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin protein zero. Muscle Nerve 2010;41(4):550-4. PMID 19882637
104: Senderek J, Hermanns B, Bergmann C, et al. X-linked dominant Charcot-Marie Tooth neuropathy: clinical, electrophysiological, and morphological phenotype in four families with different connexin 32 mutations (1). J Neurol Sci 1999;167:90-101. PMID 10521546
105: Senderek J, Ramaekers VT, Zerres K, et al. Phenotypic variation of a novel nonsense mutation in the P0 intracellular domain. J Neurol Sci 2001;192:49-51. PMID 11701152
106: Sereda M, Griffiths I, Puhlhofer A, et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 1996;16:1049-60. PMID 8630243
107: Shizuka M, Ikeda Y, Watanabe M, et al. A novel mutation of the myelin P0 gene segregating Charcot-Marie-Tooth disease type 1B manifesting as trigeminal nerve thickening. J Neurol Neurosurg Psychiatry 1999;67:250-1. PMID 10475757
108: Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127:371-84. PMID 14711881
109: Silander K, Meretoja P, Nelis E, et al. A de novo duplication in 17p11.2 and a novel mutation in the Po gene in two Dejerine-Sottas syndrome patients. Hum Mutat 1996;8:304-10. PMID 8956034
110: Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet 1974;6(2):98-118. PMID 4430158
111: Sowden JE, Logigian EL, Malik K, Herrmann DN. Genotype-phenotype correlation in a family with late onset CMT and an MPZ lys236del mutation. J Neurol Neurosurg Psychiatry 2005;76(3):442-4. PMID 15716547
112: Su Y, Brooks DG, Li L, et al. Myelin protein zero gene mutated in Charcot-Marie-Tooth disease type 1B patients. Proc Natl Acad Sci U S A 1993;90:10856-60. PMID 7504284
113: Taroni F, Botti S, Sghirlanzoni A, Pareyson D. PMP22 and MPZ point mutations in Italian families with hereditary neuropathy with liability to pressure palsies (HNPP) and Dejerine-Sottas disease (DSD). Am J Hum Genet 1996;59(4):A288.
114: Thomas FP, Geller TJ, Hahn AF, et al. Modification of CMT1A phenotypes by independent co-existing neurogenetic disorders, McArdle disease and chromosome 5p trisomy. Ann N Y Acad Sci 1999;883:472-6. PMID 10586277
115: Thomas FP, Lebo RV, Rosoklija G, et al. Tomaculous neuropathy in chromosome 1 Charcot-Marie-Tooth syndrome. Acta Neuropathol 1994;87:91-7. PMID 7511317
116: Thomas FP, Shy M, Herrmann D, et al. Preliminary phase 2 results for ACE-083, local muscle therapeutic, in patients with CMT1 and CMTX. Peripheral Nerve Society Annual Meeting 2018. Baltimore, MD: July 21-25, 2018.
117: Tooth HH. The peroneal type of progressive muscular atrophy. London: HK Lewis, 1886.
118: Vance JM, Nicholson GA, Yamaoka LH, et al. Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol 1989;104:186-9. PMID 2707366
119: van Doormaal TP, van Ruissen F, Miller KJ, Hoogendijk JE. Effective cauda equina decompression in two siblings with Charcot-Marie-Tooth disease type 1B. Neuromuscul Disord 2016;26(12):837-40. PMID 27614573
120: Verhoeven K, Villanova M, Rossi A, Malandrini A, De Jonghe P, Timmerman V. Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1. Am J Hum Genet 2001;69:889-94. PMID 11533914
121: Warner LE, Hilz MJ, Appel SH, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996;17:451-60. PMID 8816708
122: Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR-2) gene are associated with hereditary myelinopathies. Nat Genet 1998;18:382-4. PMID 9537424
123: Warner LE, Roa BB, Lupski JR. Settling the myelin protein zero question in CMT1B. Nat Genet 1995;11:119-20. PMID 7550336
124: Watanabe M, Yamamoto N, Ohkoshi N, et al. Corticosteroid-responsive asymmetric neuropathy with myelin protein zero gene mutation. Neurology 2002;59:767-9. PMID 12221176
125: Wolf C, Arnold H, Reichenbach H, Froster U. Screening of myelin gene in CMT1 patients without duplication in chromosomal region 17p11.2-p12. J Periph Nerv Syst 1997;2:402.
126: Wrabetz L, D'Antonio M, Dati G, et al. Transgenic mouse models of CMT1B neuropathy reveal gain of abnormal MPZ function. Proceedings of the first European and North American Charcot-Marie-Tooth Consortium Meeting; July 8-10, 2004; Anwerpen, Belgium
127: Xu W, Manichella D, Jiang H, et al. Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis. J Neurosci Res 2000;60:714-24. PMID 10861783
128: Yin X, Kidd GJ, Wrabetz L, Feltri ML, Messing A, Trapp BD. Schwann cell myelination requires timely and precise targeting of P(0) protein. J Cell Biol 2000;148:1009-20. PMID 10704450
129: Yiu EM, Wanigasinghe W, Mackay MT, Gonzales M, Nicholson GA, Ryan MM. Infantile-onset myelin protein zero-related demyelinating neuropathy presenting as an upper extremity monoplegia. Semin Pediatr Neurol 2018;26:52-5. PMID 29961519
130: Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIf1Bbeta. Cell 2001;105:587-97. PMID 11389829
131: Zielasek J, Martini R, Suter U, Toyka KV. Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 2000;23:696-701. PMID 10797391

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Florian P Thomas MD MA PhD MS

Dr. Thomas of Hackensack Meridian School of Medicine has no relevant financial relationships to disclose.
See Profile
Francisco de Assis Aquino Gondim MD MSc PhD

Dr. Gondim of Universidade Federal Ceará, Fortaleza, Brazil, received consulting and speaker fees from Pfizer and PTC Therapeutics and travel grants from Daiichi Sankyo Brasil.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Gisele Oliveira MD

Patient Profile

Age range of presentation: 2 to 64 years
Sex preponderance: male=female
Heredity: heredity is a factor

autosomal dominant
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Charcot-Marie-Tooth disease: 356.1

Dejerine-Sottas syndrome: 356.0

Hereditary neuropathies: 356
ICD-10: Hereditary motor and sensory neuropathy: G60.0
OMIM: Charcot-Marie-Tooth disease 1B: #118200

Dejerine-Sottas syndrome: #145900

Myelin protein zero: *159440

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Charcot-Marie-Tooth disease type 1B and other CMT neuropathies associated with MPZ mutations

Associated Disorders

Congenital hypomyelination neuropathy
Dejerine-Sottas syndrome
Hereditary motor and sensory neuropathy type 3
Peroneal muscular atrophy

Differential Diagnosis

Charcot-Marie-Tooth disease type 1A
Charcot-Marie-Tooth disease X
Charcot-Marie-Tooth disease type 2
Dejerine-Sottas syndrome
congenital hypomyelination neuropathy
- associated acquired neuropathies

Also Relevant

Charcot-Marie-Tooth disease type 1A
Charcot-Marie-Tooth disease type X
Charcot-Marie-Tooth disease: CMT2, CMT4, and others
Clinical evaluation of peripheral neuropathies
Hereditary neuropathy with predisposition to pressure palsy
- Molecular diagnosis of neurogenetic disorders

Charcot-Marie-Tooth disease type 1B (CMT1b) …

Charcot-Marie-Tooth disease type 1B and other CMT neuropathies associated with MPZ mutations

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

Carpal tunnel syndrome

Charcot-Marie-Tooth disease type 1B and other CMT neuropathies associated with MPZ mutations

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Familial dysautonomia

Peripheral nerve complications of HIV-1 infection

Neuropathies associated with cytomegalovirus infection

Disulfiram neuropathy

Mercury neuropathy

Clinical evaluation of peripheral neuropathies

Carpal tunnel syndrome

This is an article preview.
Start a Free Account
to access the full version.